This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Swerdlow, A. J. Articles by Shalet, S. M. Search for Related Content PubMed PubMed Citation Articles by Swerdlow, A. J. Articles by Shalet, S. M.

Growth Hormone Treatment of Children with Brain Tumors and Risk of Tumor Recurrence¹

Section of Epidemiology, Institute of Cancer Research (A.J.S., C.D.H.), Sutton, Surrey SM2 5NG; Departments of Endocrinology (R.E.R., S.M.S.) and Medical Statistics (W.D.J.R.), Christie Hospital, Manchester, London; Centre of Paediatric Endocrinology and Metabolism, Middlesex Hospital (H.A.S., C.G.D.B., P.C.H.), London; Department of Neurosurgery, Great Ormond Street Hospital (K.P., R.D.H.), London; and Academic Department of Radiotherapy and Oncology, Royal Marsden Hospital National Health Service Trust (M.B.), Sutton, Surrey, United Kingdom

Address all correspondence and requests for reprints to: Prof. A. J. Swerdlow, Institute of Cancer Research, Section of Epidemiology, D Block, Cotswold Road, Sutton, Surrey, United Kingdom SM2 5NG.

GH is increasingly used for treatment of children and adults. It is mitogenic, however, and there is therefore concern about its safety, especially when used to treat cancer patients who have become GH deficient after cranial radiotherapy. We followed 180 children with brain tumors attending three large hospitals in the United Kingdom and treated with GH during 1965–1996, and 891 children with brain tumors at these hospitals who received radiotherapy but not GH. Thirty-five first recurrences occurred in the GH-treated children and 434 in the untreated children. The relative risk of first recurrence in GH-treated compared with untreated patients, adjusted for potentially confounding prognostic variables, was decreased (0.6; 95% confidence interval, 0.4–0.9) as was the relative risk of mortality (0.5; 95% confidence interval, 0.3–0.8). There was no significant trend in relative risk of recurrence with cumulative time for which GH treatment had been given or with time elapsed since this treatment started. The relative risk of mortality increased significantly with time since first GH treatment. The results, based on much larger numbers than previous studies, suggest that GH does not increase the risk of recurrence of childhood brain tumors, although the rising trend in mortality relative risks with longer follow-up indicates the need for continued surveillance.

This article has been cited by other articles:

				S. J. Laughton, T. E. Merchant, C. A. Sklar, L. E. Kun, M. Fouladi, A. Broniscer, E. B. Morris, R. P. Sanders, M. J. Krasin, J. Shelso, et al. Endocrine Outcomes for Children With Embryonal Brain Tumors After Risk-Adapted Craniospinal and Conformal Primary-Site Irradiation and High-Dose Chemotherapy With Stem-Cell Rescue on the SJMB-96 Trial J. Clin. Oncol., March 1, 2008; 26(7): 1112 - 1118. [Abstract] [Full Text] [PDF]

				B. Ergun-Longmire, A. C. Mertens, P. Mitby, J. Qin, G. Heller, W. Shi, Y. Yasui, L. L. Robison, and C. A. Sklar Growth Hormone Treatment and Risk of Second Neoplasms in the Childhood Cancer Survivor J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3494 - 3498. [Abstract] [Full Text] [PDF]

				C. Dalle and V. Claude Growth Hormone for "Antiaging" JAMA, February 22, 2006; 295(8): 889 - 889. [Full Text] [PDF]

				A. Mukherjee, S. Tolhurst-Cleaver, W. D. J. Ryder, L. Smethurst, and S. M. Shalet The Characteristics of Quality of Life Impairment in Adult Growth Hormone (GH)-Deficient Survivors of Cancer and Their Response to GH Replacement Therapy J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1542 - 1549. [Abstract] [Full Text] [PDF]

				H K Gleeson and S M Shalet The impact of cancer therapy on the endocrine system in survivors of childhood brain tumours Endocr. Relat. Cancer, December 1, 2004; 11(4): 589 - 602. [Abstract] [Full Text] [PDF]

				C. M. Brownstein, A. C. Mertens, P. A. Mitby, M. Stovall, J. Qin, G. Heller, L. L. Robison, and C. A. Sklar Factors That Affect Final Height and Change in Height Standard Deviation Scores in Survivors of Childhood Cancer Treated with Growth Hormone: A Report from the Childhood Cancer Survivor Study J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4422 - 4427. [Abstract] [Full Text] [PDF]

				J. G. Gurney, K. K. Ness, M. Stovall, S. Wolden, J. A. Punyko, J. P. Neglia, A. C. Mertens, R. J. Packer, L. L. Robison, and C. A. Sklar Final Height and Body Mass Index among Adult Survivors of Childhood Brain Cancer: Childhood Cancer Survivor Study J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4731 - 4739. [Abstract] [Full Text] [PDF]

				H. K. Gleeson, R. Stoeter, A. L. Ogilvy-Stuart, H. R. Gattamaneni, B. M. Brennan, and S. M. Shalet Improvements in Final Height Over 25 Years in Growth Hormone (GH)-Deficient Childhood Survivors of Brain Tumors Receiving GH Replacement J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3682 - 3689. [Abstract] [Full Text] [PDF]

				B Kerr, M A Einaudi, P Clayton, G Gladman, T Eden, P Saunier, D Genevieve, and N Philip Is growth hormone treatment beneficial or harmful in Costello syndrome? J. Med. Genet., June 1, 2003; 40(6): e74 - 74. [Full Text] [PDF]

				S. R. Rose Studies Reveal Minimal Cancer Risks with Growth Hormone Therapy AAP Grand Rounds, November 1, 2002; 8(5): 49 - 50. [Full Text] [PDF]

				C. A. Sklar, A. C. Mertens, P. Mitby, G. Occhiogrosso, J. Qin, G. Heller, Y. Yasui, and L. L. Robison Risk of Disease Recurrence and Second Neoplasms in Survivors of Childhood Cancer Treated with Growth Hormone: A Report from the Childhood Cancer Survivor Study J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3136 - 3141. [Abstract] [Full Text] [PDF]

				Why give a child growth hormone? DTB, March 1, 2002; 40(3): 17 - 20. [Abstract] [Full Text] [PDF]

				R. D. Murray, K. H. Darzy, H. K. Gleeson, and S. M. Shalet GH-Deficient Survivors of Childhood Cancer: GH Replacement during Adult Life J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 129 - 135. [Abstract] [Full Text] [PDF]

				C. Sklar Paying the Price for Cure--Treating Cancer Survivors with Growth Hormone J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4441 - 4443. [Full Text]